...
机译:同种异体造血细胞移植(Allo Hct)使用相关寄销杂志(HAPLO)或脐带血(UCB)后,在本生造血细胞移植(Allo HCT)后的并发症率和资源利用率
Internal Medicine Cleveland Clinic Foundation;
Quantitative Health Sciences Cleveland Clinic;
Blood &
Marrow Transplant Program Cleveland Clinic Foundation;
Blood &
Marrow Transplant The Cleveland Clinic;
Blood and Marrow Transplantation Department of Hematology and Medical Oncology Taussig Cancer;
Blood and Marrow Transplantation Department of Hematology and Medical Oncology Taussig Cancer;
Blood and Marrow Transplantation Department of Hematology and Medical Oncology Taussig Cancer;
Blood and Marrow Transplantation Department of Hematology and Medical Oncology Taussig Cancer;
Blood and Marrow Transplantation Department of Hematology and Medical Oncology Taussig Cancer;
Blood and Marrow Transplantation Department of Hematology and Medical Oncology Taussig Cancer;
Blood and Marrow Transplantation Department of Hematology and Medical Oncology Taussig Cancer;
Blood &
Marrow Transplant Program Cleveland Clinic;
Blood and Marrow Transplantation Department of Hematology and Medical Oncology Taussig Cancer;
Blood &
Marrow Transplant Cleveland Clinic;
Pharmacy Cleveland Clinic;
Blood and Marrow Transplantation Department of Hematology and Medical Oncology Taussig Cancer;
Blood and Marrow Transplantation Department of Hematology and Medical Oncology Taussig Cancer;
机译:None
机译:同种异体造血细胞移植(Allo Hct)使用相关寄销杂志(HAPLO)或脐带血(UCB)后,在本生造血细胞移植(Allo HCT)后的并发症率和资源利用率
机译:无关供体造血干细胞移植(HSCT)后的慢性移植物抗宿主病(cGVHD):无关供体(URD)脐带血(UCB)受体的应答率更高。
机译:同种异体造血细胞移植(HCT)中抑制杀伤细胞IG样受体(IKIR)匹配的影响
机译:接受同种异体造血干细胞移植的患者的供体选择:加拿大造血干细胞移植医生的优先事项评估。
机译:Haploidentical供体和脐带血异种造血细胞移植免疫重建
机译:与匹配相关捐赠者(MRD)相比,与造血细胞移植(HCT)相比,脐带血(UCB)移植的成本更高:植入和HCT后并发症的影响
机译:行业指南:生物制剂许可证应用于影响造血系统的疾病患者的造血和免疫重建的最小操作,无关异体胎盘/脐带血。